Background: Recent outbreaks of swine-origin influenza A(H3N2) variant (H3N2v) viruses have raised public health concerns. Previous studies indicated that older children and young adults had the highest levels of hemagglutination-inhibition (HI) antibodies to 2010-2011 H3N2v viruses. However, newly emerging 2013 H3N2v have acquired antigenic mutations in the hemagglutinin at amino acid position 145 (N145K/R). We estimated the levels of serologic cross-reactivity among humans primed with seasonal influenza A(H3N2) (sH3N2), using postinfection ferret antisera. We also explored age-related HI antibody responses to 2012-2013 H3N2v viruses. Methods: Human and ferret antisera were tested in HI assays against 1 representative 2012 H3N2v (145N) and 2 2013 H3N2v (145K/R) viruses, together with 9 sH3N2 viruses circulating since 1968. Results: Low levels of cross-reactivity between the H3N2v and sH3N2 viruses from the 1970s-1990s were observed using postinfection ferret antisera. The overall seroprevalence among the sH3N2-primed population against 2012-2013 H3N2v viruses was >50%, and age-related seroprevalence was observed. Seroprevalence was significantly higher to 2013 H3N2v than to 2012 H3N2v viruses among some children likely to have been primed with A/Sydney/5/97-like (145K) or A/Wuhan/359/95-like viruses (145K). Conclusions: A single substitution (N145K/R) was sufficient to affect seropositivity to H3N2v viruses in some individuals. Insight into age-related antibody responses to newly emerging H3N2v viruses is critical for risk assessment and pandemic preparedness. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Recent outbreaks of swine-origin influenza A(H3N2) variant (H3N2v) viruses have raised public health concerns. Previous studies indicated that older children and young adults had the highest levels of hemagglutination-inhibition (HI) antibodies to 2010-2011 H3N2v viruses. However, newly emerging 2013 H3N2v have acquired antigenic mutations in the hemagglutinin at amino acid position 145 (N145K/R). We estimated the levels of serologic cross-reactivity among humans primed with seasonal influenza A(H3N2) (sH3N2), using postinfection ferret antisera. We also explored age-related HI antibody responses to 2012-2013 H3N2v viruses. Methods:Human and ferret antisera were tested in HI assays against 1 representative 2012 H3N2v (145N) and 2 2013 H3N2v (145K/R) viruses, together with 9 sH3N2 viruses circulating since 1968. Results: Low levels of cross-reactivity between the H3N2v and sH3N2 viruses from the 1970s-1990s were observed using postinfection ferret antisera. The overall seroprevalence among the sH3N2-primed population against 2012-2013 H3N2v viruses was >50%, and age-related seroprevalence was observed. Seroprevalence was significantly higher to 2013 H3N2v than to 2012 H3N2v viruses among some children likely to have been primed with A/Sydney/5/97-like (145K) or A/Wuhan/359/95-like viruses (145K). Conclusions: A single substitution (N145K/R) was sufficient to affect seropositivity to H3N2v viruses in some individuals. Insight into age-related antibody responses to newly emerging H3N2v viruses is critical for risk assessment and pandemic preparedness. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Seroprevalence study; antigenic analysis; human seasonal Influenza A(H3N2) viruses; serum HI antibody response; swine-origin Influenza A(H3N2) variant viruses
Authors: D M Skowronski; C Chambers; S Sabaiduc; G De Serres; J A Dickinson; A L Winter; S J Drews; K Fonseca; H Charest; J B Gubbay; M Petric; M Krajden; T L Kwindt; C Martineau; A Eshaghi; N Bastien; Y Li Journal: Euro Surveill Date: 2015-01-29
Authors: Rebekah S Schicker; John Rossow; Seth Eckel; Nicolas Fisher; Sally Bidol; Lilith Tatham; Janice Matthews-Greer; Kevin Sohner; Andrew S Bowman; James Avrill; Tony Forshey; Lenee Blanton; C Todd Davis; John Schiltz; Susan Skorupski; LaShondra Berman; Yunho Jang; Joseph S Bresee; Stephen Lindstrom; Susan C Trock; David Wentworth; Alicia M Fry; Sietske de Fijter; Kimberly Signs; Mary DiOrio; Sonja J Olsen; Matthew Biggerstaff Journal: MMWR Morb Mortal Wkly Rep Date: 2016-10-28 Impact factor: 17.586
Authors: N N Zhou; D A Senne; J S Landgraf; S L Swenson; G Erickson; K Rossow; L Liu; K j Yoon; S Krauss; R G Webster Journal: J Virol Date: 1999-10 Impact factor: 5.103
Authors: Zhixin Feng; Janet Gomez; Andrew S Bowman; Jianqiang Ye; Li-Ping Long; Sarah W Nelson; Jialiang Yang; Brigitte Martin; Kun Jia; Jacqueline M Nolting; Fred Cunningham; Carol Cardona; Jianqiang Zhang; Kyoung-Jin Yoon; Richard D Slemons; Xiu-Feng Wan Journal: J Virol Date: 2013-05-01 Impact factor: 5.103
Authors: J M Fonville; S H Wilks; S L James; A Fox; M Ventresca; M Aban; L Xue; T C Jones; N M H Le; Q T Pham; N D Tran; Y Wong; A Mosterin; L C Katzelnick; D Labonte; T T Le; G van der Net; E Skepner; C A Russell; T D Kaplan; G F Rimmelzwaan; N Masurel; J C de Jong; A Palache; W E P Beyer; Q M Le; T H Nguyen; H F L Wertheim; A C Hurt; A D M E Osterhaus; I G Barr; R A M Fouchier; P W Horby; D J Smith Journal: Science Date: 2014-11-21 Impact factor: 47.728
Authors: Feng Liu; F Liaini Gross; Stacie N Jefferson; Crystal Holiday; Yaohui Bai; Li Wang; Bin Zhou; Min Z Levine Journal: J Clin Invest Date: 2021-04-15 Impact factor: 14.808